Digital Diagnostics With
Graphene Biosensors
Intended to rapidly test for multiple infections simultaneously without amplification or reagents.
FACTS AT A GLANCE
Overview
Check4® by IdentifySensors Biologics® is intended to be a next-generation digital diagnostic platform capable of detecting multiple pathogens within 5 minutes at the gene level.
The platform is intended to eliminate the need for enzymatic amplification and reagents. Graphene biosensors will move diagnostics beyond chemical testing into a rapid digital platform that is expected to detect pathogens at a lower limit of detection and at lower price point than the most accurate PCR tests currently on the market.
Printed biosensors on graphene isolate targeted RNA or DNA from saliva and other bodily fluids through a handheld, Bluetooth device. The platform is intended to detect the genetic material of dozens of pathogens for point-of-care and over-the-counter use.
With a target price at a fraction of current molecular tests, Check4® is intended to disrupt the PCR market for many infections. This technology has not yet been approved for sale in the United States.
FACTS AT A GLANCE
Overview
Graphene-based biosensors rapidly detect infections digitally from patient samples such as saliva
Rapid test expected to surpass the LOD performance of current PCR tests
Targeted at a fraction of the price of PCR tests
Breakthrough technology that is not molecular PCR or antigen testing
No enzymes, amplification, reagents or lab work
Planned multiplex tests for multiple simultaneous rapid detection and differentiation
Test in less than five minutes at the gene level
Results sent to smartphones, remote dashboard or a clinical database
Potential integration with health data networks
Data capturing capabilities for infectious diseases
FACTS AT A GLANCE
Check4® by IdentifySensors Biologics® is intended to be a next-generation digital diagnostic platform capable of detecting multiple pathogens within 5 minutes at the gene level.
The platform is intended to eliminate the need for enzymatic amplification and reagents. Graphene biosensors will move diagnostics beyond chemical testing into a rapid digital platform that is expected to detect pathogens at a lower limit of detection and at lower price point than the most accurate PCR tests currently on the market.
Printed biosensors on graphene isolate targeted RNA or DNA from saliva and other bodily fluids through a handheld, Bluetooth device. The platform is intended to detect the genetic material of dozens of pathogens for point-of-care and over-the-counter use.
With a target price at a fraction of current molecular tests, Check4® is intended to disrupt the PCR market for many infections. This technology has not yet been approved for sale in the United States.
Overview
FACTS AT A GLANCE
Overview
Project 1
Project 2
Project 3
Project 5
FACTS AT A GLANCE
Overview
Check4® by IdentifySensors Biologics® is intended to be a next-generation digital diagnostic platform capable of detecting multiple pathogens within 5 minutes at the gene level.
The platform is intended to eliminate the need for enzymatic amplification and reagents. Graphene biosensors will move diagnostics beyond chemical testing into a rapid digital platform that is expected to detect pathogens at a lower limit of detection and at lower price point than the most accurate PCR tests currently on the market.
Printed biosensors on graphene isolate targeted RNA or DNA from saliva and other bodily fluids through a handheld, Bluetooth device. The platform is intended to detect the genetic material of dozens of pathogens for point-of-care and over-the-counter use.
With a target price at a fraction of current molecular tests, Check4® is intended to disrupt the PCR market for many infections. This technology has not yet been approved for sale in the United States.
Overview
FACTS AT A GLANCE
Overview
Check4® by IdentifySensors Biologics® is intended to be a next-generation digital diagnostic platform capable of detecting multiple pathogens within 5 minutes at the gene level.
The platform is intended to eliminate the need for enzymatic amplification and reagents. Graphene biosensors will move diagnostics beyond chemical testing into a rapid digital platform that is expected to detect pathogens at a lower limit of detection and at lower price point than the most accurate PCR tests currently on the market.
Printed biosensors on graphene isolate targeted RNA or DNA from saliva and other bodily fluids through a handheld, Bluetooth device. The platform is intended to detect the genetic material of dozens of pathogens for point-of-care and over-the-counter use.
With a target price at a fraction of current molecular tests, Check4® is intended to disrupt the PCR market for many infections. This technology has not yet been approved for sale in the United States.
Overview
FACTS AT A GLANCE
Leadership
Overview
Overview
Overview
Overview
FACTS AT A GLANCE
Leadership
Overview
Overview
Overview
FACTS AT A GLANCE
Overview
Check4® by IdentifySensors Biologics® is intended to be a next-generation digital diagnostic platform capable of detecting multiple pathogens within 5 minutes at the gene level.
The platform is intended to eliminate the need for enzymatic amplification and reagents. Graphene biosensors will move diagnostics beyond chemical testing into a rapid digital platform that is expected to detect pathogens at a lower limit of detection and at lower price point than the most accurate PCR tests currently on the market.
Printed biosensors on graphene isolate targeted RNA or DNA from saliva and other bodily fluids through a handheld, Bluetooth device. The platform is intended to detect the genetic material of dozens of pathogens for point-of-care and over-the-counter use.
With a target price at a fraction of current molecular tests, Check4® is intended to disrupt the PCR market for many infections. This technology has not yet been approved for sale in the United States.
FACTS AT A GLANCE
Overview
Accordion 1
Lorem ipsum dolor ist amte, consectetuer adipiscing eilt. Aenean commodo ligula egget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quak felis, ultricies nec, pellentesque eu, pretium quid, sem.
Accordion 2
Lorem ipsum dolor ist amte, consectetuer adipiscing eilt. Aenean commodo ligula egget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quak felis, ultricies nec, pellentesque eu, pretium quid, sem.
Check4® by IdentifySensors Biologics® is intended to be a next-generation digital diagnostic platform capable of detecting multiple pathogens within 5 minutes at the gene level.
The platform is intended to eliminate the need for enzymatic amplification and reagents. Graphene biosensors will move diagnostics beyond chemical testing into a rapid digital platform that is expected to detect pathogens at a lower limit of detection and at lower price point than the most accurate PCR tests currently on the market.
Printed biosensors on graphene isolate targeted RNA or DNA from saliva and other bodily fluids through a handheld, Bluetooth device. The platform is intended to detect the genetic material of dozens of pathogens for point-of-care and over-the-counter use.
With a target price at a fraction of current molecular tests, Check4® is intended to disrupt the PCR market for many infections. This technology has not yet been approved for sale in the United States.
Ready to invest?
Help get this test to market soon and support the fast, accurate, and affordable smartphone-connected COVID self-test.